ImpediMed Limited
IPDQF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | $6,008 | $5,535 | $4,784 |
| % Growth | – | 8.5% | 15.7% | – |
| Cost of Goods Sold | – | $717 | $682 | $12,613 |
| Gross Profit | – | $5,291 | $4,853 | -$7,829 |
| % Margin | – | 88.1% | 87.7% | -163.6% |
| R&D Expenses | – | $0 | $1,767 | $125 |
| G&A Expenses | – | $3,142 | $2,899 | $1,679 |
| SG&A Expenses | – | $14,032 | $11,735 | $4,131 |
| Sales & Mktg Exp. | – | $10,890 | $524 | $2,452 |
| Other Operating Expenses | – | $2,836 | -$19,181 | $0 |
| Operating Expenses | – | $16,868 | -$5,679 | $4,256 |
| Operating Income | – | -$11,577 | $10,532 | -$12,085 |
| % Margin | – | -192.7% | 190.3% | -252.6% |
| Other Income/Exp. Net | – | $442 | -$20,591 | $7,236 |
| Pre-Tax Income | – | -$11,135 | -$10,059 | -$10,236 |
| Tax Expense | – | $11 | $13 | -$518 |
| Net Income | – | -$11,146 | -$10,072 | -$9,718 |
| % Margin | – | -185.5% | -182% | -203.1% |
| EPS | – | 0 | -0.005 | -0.005 |
| % Growth | – | 100% | 0% | – |
| EPS Diluted | – | 0 | -0.005 | -0.005 |
| Weighted Avg Shares Out | – | 2,229,200,000 | 2,045,907 | 1,997,847 |
| Weighted Avg Shares Out Dil | – | 2,023,322,997 | 2,045,634 | 1,997,847 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $442 | $1,352 | $883 |
| Interest Expense | – | $0 | $88 | $49 |
| Depreciation & Amortization | – | $2,207 | $291 | $1,164 |
| EBITDA | – | -$9,373 | -$10,830 | -$5,295 |
| % Margin | – | -156% | -195.7% | -110.7% |